Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment (Q34188511)

31 July 2017

1 reference

title

Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment (English)

1 reference

31 July 2017

Brockmöller J

1

1 reference

31 July 2017

Kirchheiner J

series ordinal

2

1 reference

31 July 2017

Meisel C

series ordinal

3

1 reference

31 July 2017

Roots I

series ordinal

4

1 reference

31 July 2017

1 May 2000

1 reference

31 July 2017

1 reference

31 July 2017

1

1 reference

31 July 2017

2

1 reference

31 July 2017

125-151

1 reference

Omeprazole drug interaction studies

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Assessment of liver metabolic function. Clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Polymorphic hydroxylation of Debrisoquine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Dopamine formation from tyramine by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Steady State Concentrations of the Enantiomers of Mianserin and Desmethylmianserin in Poor and in Homozygous and Heterozygous Extensive Metabolizers of Debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Stereoselective disposition and pharmacologic activity of propafenone enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Management of bowel obstruction in advanced and terminal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Substantial rise in sparteine metabolic ratio during haloperidol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Gliclazide hydroxylation by rat liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14622416.1.2.125

21 January 2018

Identifiers

DOI

10.1517/14622416.1.2.125

1 reference

31 July 2017

1 reference